Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease
- Resource Type
- Article
- Authors
- Saraf, Santosh L.; Hagar, Robert; Idowu, Modupe; Osunkwo, Ifeyinwa; Cruz, Kimberly; Kuypers, Frans A.; Brown, R. Clark; Geib, James; Ribadeneira, Maria; Schroeder, Patricia; Wu, Eric; Forsyth, Sanjeev; Kelly, Patrick F.; Kalfa, Theodosia A.; Telen, Marilyn J.
- Source
- In Blood Advances 27 August 2024 8(16):4459-4475
- Subject
- Clinical Trials and Observations
Red Cells, Iron, and Erythropoiesis
- Language
- ISSN
- 2473-9529